Europe Human Insulin Market Size, Share & Trends Analysis Report By Indication, By Product Type (Pens, Syringes, and Others), By Type of Insulin, By Distribution Channel, By Country and Growth Forecast, 2024 - 2031

Europe Human Insulin Market Size, Share & Trends Analysis Report By Indication, By Product Type (Pens, Syringes, and Others), By Type of Insulin, By Distribution Channel, By Country and Growth Forecast, 2024 - 2031


The Europe Human Insulin Market would witness market growth of 2.9% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Human Insulin Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $1,389.5 million by 2031. The UK market is exhibiting a CAGR of 2% during (2024 - 2031). Additionally, The France market would experience a CAGR of 4% during (2024 - 2031).

Advancements in insulin delivery systems have also contributed significantly to the growth of the insulin market. Insulin pens, for example, offer a more user-friendly and portable alternative to traditional vial-and-syringe methods, making insulin administration less intimidating and more accurate. Government initiatives and healthcare policies are crucial in shaping the human insulin market. Public health campaigns and educational initiatives also raise awareness about diabetes prevention and management, encouraging early diagnosis and proper treatment.

Rising awareness and education about diabetes management and the importance of insulin therapy have significantly improved diagnosis rates and treatment adherence. Public health campaigns, patient and provider education programs, initiatives in schools and workplaces, the efforts of non-profit organizations, and technological advancements have all contributed to this positive trend. These endeavors have improved health outcomes, enhanced the quality of care, and promoted the growth of the insulin market by ensuring that individuals are well-informed about diabetes and the critical role of insulin in its management.

France is experiencing a similar trend, with an aging population contributing to the increasing demand for insulin. According to the French National Institute of Statistics and Economic Studies (INSEE), in 2040, there would be 51 people aged 65 or over per 100 people aged 20 to 64, compared with 37 in 2021. The French Health Ministry estimates that approximately 3.5 million people in France have diabetes, and the prevalence is higher among older adults. Public health campaigns and initiatives by the French government aim to improve diabetes detection and management, ensuring patients receive appropriate care. The growing number of senior people in France, which has led to an increase in the number of people diagnosed with diabetes, is the primary factor driving the need for the insulin in the country. Hence, these elements will support the regional market's growth in the coming years.

Based on Indication, the market is segmented into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Based on Product Type, the market is segmented into Pens, Syringes, and Others. Based on Type of Insulin, the market is segmented into Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled
  • MannKind Corporation
  • Lupin Limited
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Eli Lilly And Company
  • Medtronic PLC
  • Biocon Limited
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
Europe Human Insulin Market Report Segmentation

By Indication
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
By Product Type
  • Pens
  • Syringes
  • Others
By Type of Insulin
  • Rapid-acting insulin
  • Short-acting insulin
  • Intermediate-acting insulin
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Human Insulin Market, by Indication
1.4.2 Europe Human Insulin Market, by Product Type
1.4.3 Europe Human Insulin Market, by Type of Insulin
1.4.4 Europe Human Insulin Market, by Distribution Channel
1.4.5 Europe Human Insulin Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Europe Human Insulin Market by Indication
4.1 Europe Type 1 Diabetes Market by Country
4.2 Europe Type 2 Diabetes Market by Country
4.3 Europe Gestational Diabetes Market by Country
Chapter 5. Europe Human Insulin Market by Product Type
5.1 Europe Pens Market by Country
5.2 Europe Syringes Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Human Insulin Market by Type of Insulin
6.1 Europe Rapid-acting insulin Market by Country
6.2 Europe Short-acting insulin Market by Country
6.3 Europe Intermediate-acting insulin Market by Country
6.4 Europe Others Market by Country
Chapter 7. Europe Human Insulin Market by Distribution Channel
7.1 Europe Hospital Pharmacies Market by Country
7.2 Europe Drug Stores & Retail Pharmacies Market by Country
7.3 Europe Online Providers Market by Country
Chapter 8. Europe Human Insulin Market by Country
8.1 Germany Human Insulin Market
8.1.1 Germany Human Insulin Market by Indication
8.1.2 Germany Human Insulin Market by Product Type
8.1.3 Germany Human Insulin Market by Type of Insulin
8.1.4 Germany Human Insulin Market by Distribution Channel
8.2 UK Human Insulin Market
8.2.1 UK Human Insulin Market by Indication
8.2.2 UK Human Insulin Market by Product Type
8.2.3 UK Human Insulin Market by Type of Insulin
8.2.4 UK Human Insulin Market by Distribution Channel
8.3 France Human Insulin Market
8.3.1 France Human Insulin Market by Indication
8.3.2 France Human Insulin Market by Product Type
8.3.3 France Human Insulin Market by Type of Insulin
8.3.4 France Human Insulin Market by Distribution Channel
8.4 Russia Human Insulin Market
8.4.1 Russia Human Insulin Market by Indication
8.4.2 Russia Human Insulin Market by Product Type
8.4.3 Russia Human Insulin Market by Type of Insulin
8.4.4 Russia Human Insulin Market by Distribution Channel
8.5 Spain Human Insulin Market
8.5.1 Spain Human Insulin Market by Indication
8.5.2 Spain Human Insulin Market by Product Type
8.5.3 Spain Human Insulin Market by Type of Insulin
8.5.4 Spain Human Insulin Market by Distribution Channel
8.6 Italy Human Insulin Market
8.6.1 Italy Human Insulin Market by Indication
8.6.2 Italy Human Insulin Market by Product Type
8.6.3 Italy Human Insulin Market by Type of Insulin
8.6.4 Italy Human Insulin Market by Distribution Channel
8.7 Rest of Europe Human Insulin Market
8.7.1 Rest of Europe Human Insulin Market by Indication
8.7.2 Rest of Europe Human Insulin Market by Product Type
8.7.3 Rest of Europe Human Insulin Market by Type of Insulin
8.7.4 Rest of Europe Human Insulin Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Biocon Limited
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Research & Development Expenses
9.2 Tonghua Dongbao Pharmaceutical Co., Ltd.
9.2.1 Company Overview
9.3 Lupin Limited
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 SWOT Analysis
9.4 MannKind Corporation
9.4.1 Company Overview
9.4.2 Financial Analysis
9.5 Sanofi S.A.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 SWOT Analysis
9.6 Novo Nordisk A/S
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental & Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 SWOT Analysis
9.7 Medtronic PLC
9.7.1 Company overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 SWOT Analysis
9.8 Eli Lilly And Company
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 SWOT Analysis
9.9 Pfizer, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional & Segmental Analysis
9.9.4 Research & Development Expense
9.9.5 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings